ABSTRACT Background: In a Phase II study RRx-001 was combined with Etoposide
platinum (EP) in previously platinum treated SCLC. We correlated expression of the M2 …

Background This exploratory single-arm phase II study evaluated the efficacy and safety of
RRx-001 followed by reintroduction of platinum plus etoposide in patients with previously …

RRx-001 is a cysteine-directed anticancer alkylating agent with activity in a Phase II study in
platinum refractory small cell lung cancer. Here, we describe the design of REPLATINUM …

7079 Background: NK012 is a topoisomerase I (TI) inhibitor designed as a micelle-forming
macromolecule to release a gradual and sustained concentration of SN-38, the active …

As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug
Administration-approved treatment or a known cure, the prognosis of recurrent extensive …

7159 Background: BB-10901 is an immunoconjugate created by conjugation of the cytotoxic
maytansinoid drug DM1 to a humanized version of the murine monoclonal antibody N901 …

PURPOSE: This multicenter phase II trial was performed to determine tumor efficacy and
tolerance of the oral platinum drug JM216 in patients with small-cell lung cancer (SCLC) …

RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in
advanced non-small cell lung cancer, small-cell lung cancer and high-grade …

Introduction One-size-fits-all chemotherapy does not improve survival in patients with small
cell lung cancer (SCLC). Excision repair cross-complementing group 1 (ERCC1) …

Background ES-SCLC is highly aggressive and despite high response rates to first-line
therapy, disease progression often occurs within 6 months. There are limited later-line …